Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders
CA 2200040 A1 · Owner: Knolle, Jochen · Inventors: Hropot, Max; Bickel, Martin; Wirth, Klaus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of bradykinin antagonists for the production ofpharmaceuticals for the treatment of chronic fibrogenetic liver disorders (hepatic cirrhosis and hepatic fibrosis) and acute liver disorders and for the prevention of complications, in particular for the prophylaxis or treatment of portal hypertension decompensation phenomena such as ascites edema formation, hepatorenal, syndrome hypertensive gastropathy and colopathy splenomegaly and hemorrhagic, complications in the gastrointestinal tract due to portal hypertension collateral, circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 14, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 14, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 14, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.